William Lis

Insider · Director · ZLAB

William Lis files insider transactions with the SEC as a director of Zai Lab (ZLAB). We hold 2 disclosed purchases and sales filed since 27 March 2014, 2 of them in the last 90 days.

Files forZLAB
Disclosed buys and sells2 in all, 2 in the last 90 days
Last disclosure13 August 2026

Positions held

4 posts we hold — a term names its own dates; a run of filings only says when they filed

Filed 5 January 2021 — 12 August 2026Director · Zai Lab (ZLAB)15 Form 4 lines · source: SEC Form 4
Filed 21 March 2022 — 13 October 2023Director · Jasper Therapeutics (JSPR)10 Form 4 lines · source: SEC Form 4
Filed 4 December 2018 — 26 January 2021Director · Eidos Therapeutics (EIDX)6 Form 4 lines · source: SEC Form 4
Filed 26 March 2014 — 23 August 2018Chief Executive Officer · Portola Pharmaceuticals (PTLA)120 Form 4 lines · source: SEC Form 4

Everything they disclosed

120 entries, newest first — one per disclosure report, one per Form 4 line

▼ sold on the open market 8,506 shares of Zai LabSEC Form 413 August 2026American Depositary Shares · traded 12 August 2026 · filed 13 August 2026
▼ sold on the open market 7,040 shares of Zai LabSEC Form 424 June 2026American Depositary Shares · traded 22 June 2026 · filed 24 June 2026
was granted 22,371 shares of Zai LabSEC Form 422 June 2026American Depositary Shares · traded 17 June 2026 · filed 22 June 2026
was granted 10,831 shares of Zai LabSEC Form 423 June 2025American Depositary Shares · traded 18 June 2025 · filed 23 June 2025
▼ sold on the open market 13,814 shares of Zai LabSEC Form 423 June 2025American Depositary Shares · traded 20 June 2025 · filed 23 June 2025
▼ sold on the open market 15,000 shares of Zai LabSEC Form 44 March 2025American Depositary Shares · traded 28 February 2025 · filed 4 March 2025
▼ sold on the open market 10,297 shares of Zai LabSEC Form 43 July 2024American Depositary Shares · traded 1 July 2024 · filed 3 July 2024
▼ sold on the open market 100 shares of Zai LabSEC Form 43 July 2024American Depositary Shares · traded 1 July 2024 · filed 3 July 2024
was granted 21,253 shares of Zai LabSEC Form 420 June 2024American Depositary Shares · traded 18 June 2024 · filed 20 June 2024
▼ sold on the open market 7,965 shares of Jasper TherapeuticsSEC Form 413 October 2023Voting Common Stock · traded 13 October 2023 · filed 13 October 2023
was granted 18,903 shares of Zai LabSEC Form 430 June 2023American Depositary Shares · traded 29 June 2023 · filed 30 June 2023
was granted 47,000 shares of Jasper Therapeutics (a derivative holding)SEC Form 48 June 2023Stock Option (right to buy) · traded 7 June 2023 · filed 8 June 2023
▼ sold on the open market 8,500 shares of Jasper TherapeuticsSEC Form 414 April 2023Voting Common Stock · traded 13 April 2023 · filed 14 April 2023
▼ sold on the open market 5,434 shares of Zai LabSEC Form 47 March 2023American Depositary Shares · traded 3 March 2023 · filed 7 March 2023
was granted 29,500 shares of Jasper TherapeuticsSEC Form 413 October 2022Voting Common Stock · traded 12 October 2022 · filed 13 October 2022
▼ sold on the open market 24,743 shares of Jasper TherapeuticsSEC Form 428 June 2022Voting Common Stock · traded 24 June 2022 · filed 28 June 2022
▼ sold on the open market 24,743 shares of Jasper TherapeuticsSEC Form 428 June 2022Voting Common Stock · traded 27 June 2022 · filed 28 June 2022
was granted 7,500 shares of Jasper Therapeutics (a derivative holding)SEC Form 423 March 2022Stock Option (right to buy) · traded 21 March 2022 · filed 23 March 2022
was granted 89,972 shares of Jasper Therapeutics (a derivative holding)SEC Form 423 March 2022Stock Option (right to buy) · traded 21 March 2022 · filed 23 March 2022
was granted 100,000 shares of Jasper Therapeutics (a derivative holding)SEC Form 423 March 2022Stock Option (right to buy) · traded 21 March 2022 · filed 23 March 2022
was granted 89,972 shares of Jasper TherapeuticsSEC Form 423 March 2022Voting Common Stock · traded 21 March 2022 · filed 23 March 2022
had shares withheld for tax on 5,350 shares of Zai LabSEC Form 414 February 2022Ordinary Shares · traded 5 January 2021 · filed 14 February 2022
▼ sold on the open market 1,926 shares of Zai LabSEC Form 421 January 2022Ordinary Shares · traded 20 January 2022 · filed 21 January 2022
was granted 7,763 shares of Zai LabSEC Form 44 January 2022Ordinary Shares · traded 3 January 2022 · filed 4 January 2022
returned to the issuer 21,528 shares of Eidos Therapeutics (a derivative holding)SEC Form 428 January 2021Stock Option (Right to Buy) · traded 26 January 2021 · filed 28 January 2021
returned to the issuer 21,528 shares of Eidos Therapeutics (a derivative holding)SEC Form 428 January 2021Stock Option (Right to Buy) · traded 26 January 2021 · filed 28 January 2021
returned to the issuer 43,056 shares of Eidos Therapeutics (a derivative holding)SEC Form 428 January 2021Stock Option (Right to Buy) · traded 26 January 2021 · filed 28 January 2021
was granted 3,852 shares of Zai LabSEC Form 420 January 2021Ordinary Shares · traded 15 January 2021 · filed 20 January 2021
was granted 21,528 shares of Eidos Therapeutics (a derivative holding)SEC Form 429 May 2020Stock Option (right to buy) · traded 27 May 2020 · filed 29 May 2020
was granted 21,528 shares of Eidos Therapeutics (a derivative holding)SEC Form 413 June 2019Stock Option (right to buy) · traded 12 June 2019 · filed 13 June 2019
was granted 43,056 shares of Eidos Therapeutics (a derivative holding)SEC Form 47 December 2018Stock Option (right to buy) · traded 4 December 2018 · filed 7 December 2018
exercised options over 35,000 shares of Portola PharmaceuticalsSEC Form 428 August 2018Common Stock · traded 28 July 2018 · filed 28 August 2018
had shares withheld for tax on 17,587 shares of Portola PharmaceuticalsSEC Form 428 August 2018Common Stock · traded 23 August 2018 · filed 28 August 2018
▼ sold on the open market 5,113 shares of Portola PharmaceuticalsSEC Form 48 June 2018Common Stock · traded 6 June 2018 · filed 8 June 2018
was granted 12,890 shares of Portola PharmaceuticalsSEC Form 424 May 2018Common Stock · traded 22 May 2018 · filed 24 May 2018
had shares withheld for tax on 6,491 shares of Portola PharmaceuticalsSEC Form 424 May 2018Common Stock · traded 22 May 2018 · filed 24 May 2018
had shares withheld for tax on 19,184 shares of Portola PharmaceuticalsSEC Form 46 March 2018Common Stock · traded 2 March 2018 · filed 6 March 2018
was granted 100,000 shares of Portola Pharmaceuticals (a derivative holding)SEC Form 42 February 2018Stock Option (Right to Buy) · traded 31 January 2018 · filed 2 February 2018
was granted 25,000 shares of Portola PharmaceuticalsSEC Form 42 February 2018Common Stock · traded 31 January 2018 · filed 2 February 2018
had shares withheld for tax on 7,435 shares of Portola PharmaceuticalsSEC Form 418 August 2017Common Stock · traded 16 August 2017 · filed 18 August 2017
exercised options over 95,850 shares of Portola PharmaceuticalsSEC Form 429 June 2017Common Stock · traded 27 June 2017 · filed 29 June 2017
exercised options over 55,000 shares of Portola PharmaceuticalsSEC Form 429 June 2017Common Stock · traded 27 June 2017 · filed 29 June 2017
exercised options over 14,285 shares of Portola PharmaceuticalsSEC Form 429 June 2017Common Stock · traded 27 June 2017 · filed 29 June 2017
exercised options over 70,014 shares of Portola PharmaceuticalsSEC Form 429 June 2017Common Stock · traded 27 June 2017 · filed 29 June 2017
exercised options over 20,000 shares of Portola PharmaceuticalsSEC Form 429 June 2017Common Stock · traded 27 June 2017 · filed 29 June 2017
▼ sold on the open market 129,271 shares of Portola PharmaceuticalsSEC Form 429 June 2017Common Stock · traded 27 June 2017 · filed 29 June 2017
▼ sold on the open market 112,778 shares of Portola PharmaceuticalsSEC Form 429 June 2017Common Stock · traded 27 June 2017 · filed 29 June 2017
▼ sold on the open market 13,100 shares of Portola PharmaceuticalsSEC Form 429 June 2017Common Stock · traded 27 June 2017 · filed 29 June 2017
exercised options over 14,150 shares of Portola PharmaceuticalsSEC Form 429 June 2017Common Stock · traded 28 June 2017 · filed 29 June 2017
▼ sold on the open market 14,150 shares of Portola PharmaceuticalsSEC Form 429 June 2017Common · traded 28 June 2017 · filed 29 June 2017
exercised options over 95,850 shares of Portola Pharmaceuticals (a derivative holding)SEC Form 429 June 2017Stock Option (Right to Buy) · traded 27 June 2017 · filed 29 June 2017
exercised options over 55,000 shares of Portola Pharmaceuticals (a derivative holding)SEC Form 429 June 2017Stock Option (Right to Buy) · traded 27 June 2017 · filed 29 June 2017
exercised options over 14,285 shares of Portola Pharmaceuticals (a derivative holding)SEC Form 429 June 2017Stock Option (Right to Buy) · traded 27 June 2017 · filed 29 June 2017
exercised options over 70,014 shares of Portola Pharmaceuticals (a derivative holding)SEC Form 429 June 2017Stock Option (Right to Buy) · traded 27 June 2017 · filed 29 June 2017
exercised options over 20,000 shares of Portola Pharmaceuticals (a derivative holding)SEC Form 429 June 2017Stock Option (Right to Buy) · traded 27 June 2017 · filed 29 June 2017
exercised options over 14,150 shares of Portola Pharmaceuticals (a derivative holding)SEC Form 429 June 2017Stock Option (Right to Buy) · traded 28 June 2017 · filed 29 June 2017
▼ sold on the open market 6,750 shares of Portola PharmaceuticalsSEC Form 414 April 2017Common Stock · traded 11 April 2017 · filed 14 April 2017
▼ sold on the open market 6,750 shares of Portola PharmaceuticalsSEC Form 411 April 2017Common Stock · traded 11 April 2017 · filed 11 April 2017
had shares withheld for tax on 13,669 shares of Portola PharmaceuticalsSEC Form 43 March 2017Common Stock · traded 2 March 2017 · filed 3 March 2017
was granted 34,375 shares of Portola PharmaceuticalsSEC Form 41 February 2017Common Stock · traded 30 January 2017 · filed 1 February 2017
was granted 137,500 shares of Portola Pharmaceuticals (a derivative holding)SEC Form 41 February 2017Stock Option (Right to Buy) · traded 30 January 2017 · filed 1 February 2017
was granted 34,375 shares of Portola Pharmaceuticals (a derivative holding)SEC Form 41 February 2017Performance Stock Unit · traded 30 January 2017 · filed 1 February 2017
▼ sold on the open market 5,675 shares of Portola PharmaceuticalsSEC Form 43 May 2016Common Stock · traded 2 May 2016 · filed 3 May 2016
was granted 40,000 shares of Portola PharmaceuticalsSEC Form 43 May 2016Common Stock · traded 1 May 2016 · filed 3 May 2016
was granted 80,000 shares of Portola Pharmaceuticals (a derivative holding)SEC Form 43 May 2016Stock Option · traded 1 May 2016 · filed 3 May 2016
had shares withheld for tax on 3,492 shares of Portola PharmaceuticalsSEC Form 44 March 2016Common Stock · traded 2 March 2016 · filed 4 March 2016
was granted 28,125 shares of Portola PharmaceuticalsSEC Form 429 January 2016Common Stock · traded 27 January 2016 · filed 29 January 2016
was granted 112,500 shares of Portola Pharmaceuticals (a derivative holding)SEC Form 429 January 2016Stock Option (Right to Buy) · traded 27 January 2016 · filed 29 January 2016
was granted 28,125 shares of Portola Pharmaceuticals (a derivative holding)SEC Form 429 January 2016Performance Stock Unit · traded 27 January 2016 · filed 29 January 2016
exercised options over 50,000 shares of Portola PharmaceuticalsSEC Form 415 July 2015Common Stock · traded 15 July 2015 · filed 15 July 2015
▼ sold on the open market 50,000 shares of Portola PharmaceuticalsSEC Form 415 July 2015Common Stock · traded 15 July 2015 · filed 15 July 2015
exercised options over 50,000 shares of Portola Pharmaceuticals (a derivative holding)SEC Form 415 July 2015Stock Option (Right to Buy) · traded 15 July 2015 · filed 15 July 2015
exercised options over 15,000 shares of Portola PharmaceuticalsSEC Form 42 July 2015Common Stock · traded 2 July 2015 · filed 2 July 2015
▼ sold on the open market 15,000 shares of Portola PharmaceuticalsSEC Form 42 July 2015Common Stock · traded 2 July 2015 · filed 2 July 2015
exercised options over 15,000 shares of Portola Pharmaceuticals (a derivative holding)SEC Form 42 July 2015Stock Option (Right to Buy) · traded 2 July 2015 · filed 2 July 2015
exercised options over 15,000 shares of Portola PharmaceuticalsSEC Form 41 July 2015Common Stock · traded 30 June 2015 · filed 1 July 2015
▼ sold on the open market 5,400 shares of Portola PharmaceuticalsSEC Form 41 July 2015Common Stock · traded 30 June 2015 · filed 1 July 2015
▼ sold on the open market 9,600 shares of Portola PharmaceuticalsSEC Form 41 July 2015Common Stock · traded 30 June 2015 · filed 1 July 2015
exercised options over 15,000 shares of Portola PharmaceuticalsSEC Form 41 July 2015Common Stock · traded 1 July 2015 · filed 1 July 2015
▼ sold on the open market 14,900 shares of Portola PharmaceuticalsSEC Form 41 July 2015Common Stock · traded 1 July 2015 · filed 1 July 2015
▼ sold on the open market 100 shares of Portola PharmaceuticalsSEC Form 41 July 2015Common Stock · traded 1 July 2015 · filed 1 July 2015
exercised options over 15,000 shares of Portola Pharmaceuticals (a derivative holding)SEC Form 41 July 2015Stock Option (Right to Buy) · traded 30 June 2015 · filed 1 July 2015
exercised options over 15,000 shares of Portola Pharmaceuticals (a derivative holding)SEC Form 41 July 2015Stock Option (Right to Buy) · traded 1 July 2015 · filed 1 July 2015
exercised options over 45,000 shares of Portola PharmaceuticalsSEC Form 41 May 2015Common Stock · traded 30 April 2015 · filed 1 May 2015
▼ sold on the open market 44,900 shares of Portola PharmaceuticalsSEC Form 41 May 2015Common Stock · traded 30 April 2015 · filed 1 May 2015
▼ sold on the open market 100 shares of Portola PharmaceuticalsSEC Form 41 May 2015Common Stock · traded 30 April 2015 · filed 1 May 2015
exercised options over 45,000 shares of Portola Pharmaceuticals (a derivative holding)SEC Form 41 May 2015Stock Option (Right to Buy) · traded 30 April 2015 · filed 1 May 2015
was granted 27,500 shares of Portola PharmaceuticalsSEC Form 429 January 2015Common Stock · traded 27 January 2015 · filed 29 January 2015
was granted 130,000 shares of Portola Pharmaceuticals (a derivative holding)SEC Form 429 January 2015Stock Option (Right to Buy) · traded 27 January 2015 · filed 29 January 2015
was granted 70,000 shares of Portola Pharmaceuticals (a derivative holding)SEC Form 429 January 2015Performance Stock Unit · traded 27 January 2015 · filed 29 January 2015
exercised options over 20,000 shares of Portola PharmaceuticalsSEC Form 420 January 2015Common Stock · traded 20 January 2015 · filed 20 January 2015
▼ sold on the open market 19,800 shares of Portola PharmaceuticalsSEC Form 420 January 2015Common Stock · traded 20 January 2015 · filed 20 January 2015
▼ sold on the open market 200 shares of Portola PharmaceuticalsSEC Form 420 January 2015Common Stock · traded 20 January 2015 · filed 20 January 2015
exercised options over 6,131 shares of Portola Pharmaceuticals (a derivative holding)SEC Form 420 January 2015Stock Option (Right to Buy) · traded 20 January 2015 · filed 20 January 2015
exercised options over 13,869 shares of Portola Pharmaceuticals (a derivative holding)SEC Form 420 January 2015Stock Option (Right to Buy) · traded 20 January 2015 · filed 20 January 2015
exercised options over 6,524 shares of Portola PharmaceuticalsSEC Form 416 January 2015Common Stock · traded 15 January 2015 · filed 16 January 2015
▼ sold on the open market 6,524 shares of Portola PharmaceuticalsSEC Form 416 January 2015Common Stock · traded 15 January 2015 · filed 16 January 2015
exercised options over 13,476 shares of Portola PharmaceuticalsSEC Form 416 January 2015Common Stock · traded 16 January 2015 · filed 16 January 2015
▼ sold on the open market 12,601 shares of Portola PharmaceuticalsSEC Form 416 January 2015Common Stock · traded 16 January 2015 · filed 16 January 2015
▼ sold on the open market 875 shares of Portola PharmaceuticalsSEC Form 416 January 2015Common Stock · traded 16 January 2015 · filed 16 January 2015
exercised options over 6,524 shares of Portola Pharmaceuticals (a derivative holding)SEC Form 416 January 2015Stock Option (Right to Buy) · traded 15 January 2015 · filed 16 January 2015
exercised options over 13,476 shares of Portola Pharmaceuticals (a derivative holding)SEC Form 416 January 2015Stock Option (Right to Buy) · traded 16 January 2015 · filed 16 January 2015
exercised options over 10,000 shares of Portola PharmaceuticalsSEC Form 420 November 2014Common Stock · traded 18 November 2014 · filed 20 November 2014
▼ sold on the open market 10,000 shares of Portola PharmaceuticalsSEC Form 420 November 2014Common Stock · traded 18 November 2014 · filed 20 November 2014
exercised options over 15,000 shares of Portola PharmaceuticalsSEC Form 420 November 2014Common Stock · traded 19 November 2014 · filed 20 November 2014
▼ sold on the open market 15,000 shares of Portola PharmaceuticalsSEC Form 420 November 2014Common Stock · traded 19 November 2014 · filed 20 November 2014
exercised options over 15,000 shares of Portola PharmaceuticalsSEC Form 420 November 2014Common Stock · traded 20 November 2014 · filed 20 November 2014
▼ sold on the open market 14,800 shares of Portola PharmaceuticalsSEC Form 420 November 2014Common Stock · traded 20 November 2014 · filed 20 November 2014
▼ sold on the open market 200 shares of Portola PharmaceuticalsSEC Form 420 November 2014Common Stock · traded 20 November 2014 · filed 20 November 2014
exercised options over 10,000 shares of Portola Pharmaceuticals (a derivative holding)SEC Form 420 November 2014Stock Option (Right to Buy) · traded 18 November 2014 · filed 20 November 2014
exercised options over 15,000 shares of Portola Pharmaceuticals (a derivative holding)SEC Form 420 November 2014Stock Option (Right to Buy) · traded 19 November 2014 · filed 20 November 2014
exercised options over 15,000 shares of Portola Pharmaceuticals (a derivative holding)SEC Form 420 November 2014Stock Option (Right to Buy) · traded 20 November 2014 · filed 20 November 2014
exercised options over 10,000 shares of Portola PharmaceuticalsSEC Form 417 November 2014Common Stock · traded 13 November 2014 · filed 17 November 2014
▼ sold on the open market 8,000 shares of Portola PharmaceuticalsSEC Form 417 November 2014Common Stock · traded 13 November 2014 · filed 17 November 2014
▼ sold on the open market 2,000 shares of Portola PharmaceuticalsSEC Form 417 November 2014Common Stock · traded 13 November 2014 · filed 17 November 2014
exercised options over 10,000 shares of Portola PharmaceuticalsSEC Form 417 November 2014Common Stock · traded 14 November 2014 · filed 17 November 2014
▼ sold on the open market 10,000 shares of Portola PharmaceuticalsSEC Form 417 November 2014Common Stock · traded 14 November 2014 · filed 17 November 2014
exercised options over 1,095 shares of Portola PharmaceuticalsSEC Form 417 November 2014Common Stock · traded 17 November 2014 · filed 17 November 2014
exercised options over 8,905 shares of Portola PharmaceuticalsSEC Form 417 November 2014Common Stock · traded 17 November 2014 · filed 17 November 2014
▼ sold on the open market 10,000 shares of Portola PharmaceuticalsSEC Form 417 November 2014Common Stock · traded 17 November 2014 · filed 17 November 2014

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.